MARATTO

article

Management of hemoptysis in a pneumology department

Abstract

<b>Introduction:</b> The management of hemoptysis depends onseverity, etiology and the available therapeutic means. We aimed to describe the management of hemoptysis in a Tunisianpneumology department. <b>Methods:</b> A retrospective study was conducted in the pneumology department of Charles Nicolle hospitalof Tunis including patients hospitalized for hemoptysis between 2020 and 2022. <b>Results:</b> we included 100 patients with an average age of 54±16 years and sex ratio at 4.87(H/F). tabacco smoking was present in 83% and drug use was noticed in 13%. Comorbidities were associated in 45% dominated by diabetes and cardiac diseases. Hemoptysis was isolated in 18%,cough was the most associated symptom (70%). Pulmonary tuberculosis was the most common etiology (33.3%). Hemoptysis was mostly mild (48%), moderate (35%) and severe(16%). An etiological treatment and antihemorrhagic agent (etamsylate) and was used for all patients. Adrenaline nebulization was indicated for 31 patients. A surgical procedure was required in 11% (6 hemostasis lobectomy, 4 bronchial artery ligation and one perikystectomy). Arterial embolization was realized for one patient.the short-term evolution, linked to hemoptysis, was favourable in most cases, only one patient died of cataclysmic hemorrhage. <b>Conclusion:</b> Hemoptysis is an alarming symptom requiring a rapid management. In Tunisia, surgical techniques is an option to manage severe hemoptysis.

Research topics

  • Vascular Anomalies and Treatments
  • Tracheal and airway disorders

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1183/13993003.congress-2023.pa3316

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.